Head-to-head evidence
efpeglenatide vs XW014
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Type 2 Diabetes
Shared mechanism: GLP-1 receptor · full Type 2 Diabetes pipeline
efpeglenatide
Developed by Hanmi Pharmaceutical and partners
NCT03353350 · Phase 3 · completed
The trial was randomized, quadruple-blinded, placebo-controlled, and included 406 participants, providing a strong comparative design. However, the primary endpoint was the surrogate measure of HbA1c change, and although the reported changes favored efpeglenatide, statistical significance for the primary comparison was not reported.
Next expected readout: November 2027 · NCT07379333 (registry estimate)
XW014
Developed by Sciwind Biosciences
NCT05579314 · Phase 1 · completed
This is a randomized, blinded, placebo-controlled trial, but its primary endpoints are adverse events and routine safety measurements rather than a diabetes outcome such as blood sugar control, and no results have been posted yet.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: efpeglenatide's landscape · XW014's landscape